

## OD2A-S Performance Measures: Quick Reference Guide for Qualitative Data

This document serves as a Quick Reference Guide to qualitative data that will be entered into Partner's Portal including data for one qualitative performance measure, HE\_Impact, as well as contextual and data quality questions for all eight performance measures. All information presented in this document can be found within the *OD2A-S Performance Measures Technical Guidance v2.3 May 2025*). Additionally, this companion document can be used alongside the Excel Reporting Tool, which will capture quantitative data on seven performance measures. All data will be submitted to CDC within the Performance Measures Module of Partner's Portal.

### Qualitative Performance Measure: HE\_Impact

HE_Impact	Impactful practices for improving access to care and treatment for disproportionately affected populations
<b>Reporting Specifications</b>	<p>The following format is recommended for reporting this qualitative indicator:</p> <ol style="list-style-type: none"><li>1. Brief description of the implemented and/or tailored (<i>adapted to specific cultural, linguistic, environmental, or social needs of populations</i>) evidence-based intervention or innovative practice (<i>including setting and whether navigators were included if applicable</i>) and how these compare to previous efforts.</li><li>2. How access to care or treatment has been improved, and what new/existing community assets were leveraged.</li><li>3. Specific populations disproportionately affected by overdose and underserved with care and treatment programs are impacted by efforts (<i>if tracked</i>).</li><li>4. <i>This is optional. Any other outcomes that were improved (provides recipients the option to expand beyond access to care and include any other outcomes, for example, retention in care, decreased opioid use).</i></li></ol> <p>The length of the narrative should be succinct, but each impactful practice* should have a descriptive paragraph if more than one is outlined.</p>

## Contextual and Data Quality Questions

Label Name	Performance Measure	Contextual Questions	Data Quality Questions
<b>HE_Impact</b>	Impactful practices for improving access to care and treatment for disproportionately affected populations	<ol style="list-style-type: none"> <li>1. What barriers prevent achieving access to care and treatment for SUD?</li> <li>2. What facilitators support achieving access to care and treatment for SUD?</li> </ol>	<ol style="list-style-type: none"> <li>1. Describe any issues or concerns that impact the quality of the data shared (e.g., data completeness, data accuracy, facilitators/barriers for collection and reporting).</li> </ol>
<b>HE_Activities</b>	Number of health impact overdose prevention interventions focused on disproportionately affected populations implemented with OD2A funding	<ol style="list-style-type: none"> <li>1. Please describe the activities in this performance measure, for whom they were intended, and how the activities were implemented and/or tailored (e.g., linguistically, culturally) for disproportionately affected populations?</li> </ol>	<ol style="list-style-type: none"> <li>1. Describe any issues or concerns that impact the quality of the data shared (e.g., data completeness, data accuracy, facilitators/barriers for collection and reporting).</li> </ol>
<b>HR_Encounters</b>	Number of harm reduction service encounters at OD2A funded or supported organizations	<ol style="list-style-type: none"> <li>1. What are the barriers for people accessing harm reduction services in your jurisdiction?</li> <li>2. What are the facilitators for people accessing harm reduction services in your jurisdiction?</li> <li>3. What types of services are included?</li> <li>4. Please estimate the proportion of harm reduction service encounters that occurred:              ____% at brick-and-mortar locations              ____% via mobile-based outreach services              ____% via mail-based delivery              ____% other (please specify)           </li> </ol>	<ol style="list-style-type: none"> <li>1. Describe any issues or concerns that impact the quality of the data shared (e.g., data completeness, data accuracy, facilitators/barriers for collection and reporting).</li> <li>2. How many OD2A-funded organizations are included in the data submitted?</li> </ol>
<b>HR_Naloxone</b>	Number of naloxone doses distributed by OD2A funded or supported organizations	<ol style="list-style-type: none"> <li>1. What are barriers to accessing or receiving naloxone?</li> <li>2. What are facilitators to accessing or receiving naloxone?</li> </ol>	<ol style="list-style-type: none"> <li>1. If you selected “other” type of organizations in the reporting tool, please describe.</li> <li>2. Describe any issues or concerns that impact the</li> </ol>

		3. How did you use OD2A Funds to distribute naloxone (e.g., staffing to distribute, vending machines)? 4. <i>(Optional)</i> . Describe mechanisms used to distribute naloxone (e.g., mail in, handoffs).	quality of the data shared (e.g., data completeness, data accuracy, facilitators/barriers for collection and reporting).
<b>LTC_Navigators</b>	Number of navigators who link PWUD to care and harm reduction services via warm handoffs	1. Describe what types of navigators are included in the data reported (e.g., certified peer recovery specialists, peer support specialists, case managers, patient navigators, community health workers, persons with lived experience, etc.). 2. Describe methods to support navigators, including average hourly pay, benefits, and additional supports (e.g., trauma, wellness, emotional/psychological support, infrastructure such as a phone) to help retain them.	1. Describe any issues or concerns that impact the quality of the data shared (e.g., data completeness, data accuracy, facilitators/barriers for collection and reporting).
<b>LTC_Referrals</b>	Number of referrals to care and harm reduction services	<b>Types of Impactful Referrals</b> 1. <i>This contextual question is optional. If you have other OD2A funded or supported referrals beyond referrals to MOUD, behavioral treatment only (without MOUD), and harm reduction services. Please describe the “other” types of referrals.</i> <b>Reporting Partners</b> 2. Approximately, what % of healthcare facilities (e.g., hospitals, emergency departments, and other clinical settings) reported data to your jurisdiction for this performance measure? (If % not available, report total number of healthcare facilities that reported) 3. Approximately, what % of EMS agencies reported data to your jurisdiction for this performance measure? (If % not available, report total number of EMS agencies that reported). 4. Approximately, what % of carceral settings (e.g., prisons and jails), reported data to your	1. Describe any issues or concerns that impact the quality of the data shared (e.g., data completeness, data accuracy, facilitators/barriers for collection and reporting).

		<p>jurisdiction for this performance measure? (If % not available, report total number of carceral settings that reported).</p> <p>5. Approximately, what % of harm reduction settings (e.g., SSPs) reported data to your jurisdiction for this performance measure? (If % not available, report total number of carceral settings that reported).</p>	
<b>HS_Training</b>	Number of clinicians who received training on implementing the “2022 CDC Clinical Practice Guidelines for Prescribing Opioids for Pain”	<ol style="list-style-type: none"> <li>1. Describe the trainings including the title, number offered, length, who conducted them, and where the training occurred.</li> <li>2. This contextual question is optional. What populations are served by the clinicians who were trained?</li> <li>3. What are barriers to effectively training clinicians on the “2022 CDC Clinical Practice Guideline”?</li> <li>4. What are facilitators to effectively training clinicians on the “2022 CDC Clinical Practice Guideline”?</li> </ol>	<ol style="list-style-type: none"> <li>1. Describe any issues or concerns that impact the quality of the data shared (e.g., data completeness, data accuracy, facilitators/barriers for collection and reporting).</li> </ol>
<b>HS_SUD_Protocols</b>	Number of health/clinical settings implementing or improving protocols and/or policies for evidence-based SUD treatment or referrals	<ol style="list-style-type: none"> <li>1. Describe how access to MOUD for healthcare settings has changed since implementing policies or protocols.</li> <li>2. Describe the partnerships for SUD referral with the health settings included in this indicator. What steps were taken to develop and build the partnerships for SUD referrals?</li> </ol>	<ol style="list-style-type: none"> <li>1. What types of health settings are included in the reported data?</li> <li>2. Describe any issues or concerns that impact the quality of the data shared (e.g., data completeness, data accuracy, facilitators/barriers for collection and reporting).</li> </ol>